Fig. 2

Comparison between somatic mutations in tumour and matched plasma from patients 45 and 95. Overlaps between somatic mutation calls in tumour and baseline pre-treatment (P1) plasma (top), and combined plasma (P1-P5/P4) from baseline plus follow-up sampling (bottom) in each patient, are shown in A and B. Comparisons were used to inform the development of our custom analysis pipeline, for the identification of candidate ctDNA mutations in plasma. Enriched gene signalling pathways (Reactome) observed in tumour tissues and ctDNA variants from combined plasma samples are shown in C and D